title: Potential immunosuppressive function of plasma indoleamine 2,3-dioxygenase in patients with aGVHD after allo-HSCT.
abstract: Given the function of indoleamine 2,3-dioxygenase (IDO) in the induction of immune tolerance as a T-cell inhibitor, we investigated whether plasma IDO levels correlate with the biological activity of acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Plasma levels of IDO were monitored by ELISA in 147 samples from 65 patients who fulfilled the diagnostic histopathological and/or clinical criteria of aGVHD and 16 episodes of infection after allo-HSCT. Elevated plasma IDO levels were associated with occurrence of infection or mild aGVHD (grade I-II). Most patients with grade III-IV aGVHD had relatively low levels of IDO compared to those with mild aGVHD or infection. Responses of aGVHD to immunosuppressive therapy were associated with a decrease in IDO levels in the majority of patients with mild aGVHD, whereas secondary infection was characterized by persistent or increased IDO levels after treatment. Although plasma IDO levels may indicate the severity and outcome of aGVHD and point to appropriate therapies through its function in immune tolerance, it is not aGVHD specific and may not be a distinguishing biomarker of aGVHD.
authors.affiliation: Peking University People's Hospital Peking, University Institute of Hematology, Beijing, China.
authors.forename: Xiao-Su
authors.initials: XS
authors.lastname: Zhao
authors.forename: Kai-Yan
authors.initials: KY
authors.lastname: Liu
authors.forename: Dai-Hong
authors.initials: DH
authors.lastname: Liu
authors.forename: Lan-Ping
authors.initials: LP
authors.lastname: Xu
authors.forename: Huan
authors.initials: H
authors.lastname: Chen
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Huang
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood / Q000201:enzymology* / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007108:Immune Tolerance; D007166:Immunosuppressive Agents / Q000378:metabolism*; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000097:blood*; D007239:Infections / Q000097:blood / Q000201:enzymology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase